LONDON--(BUSINESS WIRE)--Acrongenomics Inc. (OTCBB:AGNM) & Molecular Vision, Ltd., an Imperial College spin-out company, are pleased to announce that the fundamental patent for their BioLED technology for low cost, stand-alone diagnostic devices based on organic light sources, photodetectors and microfluidic chips has been accepted in Japan. Dr. Ian Campbell, Molecular Vision’s Managing Director, said “this important addition to Molecular Vision’s patent coverage, which already includes UK, USA and Europe, is extremely pleasing as it greatly enhances our worldwide IP protection.” Dr. Dimitri Goundis, CEO of Acrongenomics added, “we are very satisfied with the granting of the patent in Japan, and the solid IP position worldwide.”
